Project Details
| Short title | R3767-ONC-2236 |
|---|---|
| Status | Active |
| Effective start/end date | 12/10/23 → 14/06/28 |
CTU: A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY), CEMIPLIMAB (ANTI-PD-1 ANTIBODY), AND CHEMOTHERAPY VERSUS CEMIPLIMAB AND CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IRRESPECTIVE OF PD-L1 EXPRESSION LEVELS
- Park, John (Primary Chief Investigator)
- Contacos, Christine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Chester, Catherine (Clinical Trial Unit Staff)
Project: Research